Evidence map›Paper›PMID 30620669›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.

Stephen M Ansell, Monique C Minnema, Peter Johnson, John M Timmerman, Philippe Armand, Margaret A Shipp, Scott J Rodig, Azra H Ligon, Margaretha G M Roemer, Nishitha Reddy and 8 more

2 registry-linked trialsOpen access · greenAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 235 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
235citing papers in PubMed, 4 pooled it
35.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05280626 phase2not yet recruitingnot on this mapstarted 2022, after this paper: background citation

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP: a Randomized, Open, Multicenter Clinical Study

TypeinterventionalSponsorInnovent Biologics (Suzhou) Co. Ltd.Ran2022 to 2026Enrolled100ConditionsDiffuse Large B-Cell LymphomaArmsSintilimab, Rituximab
NCT05816746 phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

Low-Dose Decitabine Plus Anti-PD-1 Treatment for Relapsed/Refractory Diffuse Large B Cell Lymphoma With Extranodal (Esp. Central Nervous System) Involvement: A PhaseⅡClinical Trial

TypeinterventionalSponsorChinese PLA General HospitalRan2023 to 2026Enrolled20ConditionsDiffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension, Central Nervous System LymphomaArmsLow-Dose Decitabine plus anti-PD-1
3 · Its place in the literature

Who cites it

235 citing papers in PubMed, 4 syntheses or guidelines pooled it, 360 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  6. Trial
  7. Trial
  8. CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Safety and efficacy of durvalumab with R-CHOP or RInternational journal of hematology · 2022
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Review
  19. Article
  20. Article

175 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 8 countries.

Stephen M Ansell1 Mayo Clinic, Rochester, MN.
Monique C Minnema2 University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands, on behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC.
Peter Johnson3 University of Southampton, Southampton, United Kingdom.
John M Timmerman4 University of California, Los Angeles, Los Angeles, CA.
Philippe Armand5 Dana-Farber Cancer Institute, Boston, MA.
Margaret A Shipp5 Dana-Farber Cancer Institute, Boston, MA.
Scott J Rodig5 Dana-Farber Cancer Institute, Boston, MA.
Azra H Ligon6 Brigham and Women's Hospital, Boston, MA.
Margaretha G M Roemer5 Dana-Farber Cancer Institute, Boston, MA.
Nishitha Reddy7 Vanderbilt University, Nashville, TN.
Jonathon B Cohen8 Emory University, Atlanta, GA.
Sarit Assouline9 Jewish General Hospital, Montreal, Quebec, Canada.
Michelle Poon10 National University Cancer Institute, Singapore, Singapore.
Manish Sharma11 Bristol-Myers Squibb, Princeton, NJ.
Kazunobu Kato11 Bristol-Myers Squibb, Princeton, NJ.
Selda Samakoglu11 Bristol-Myers Squibb, Princeton, NJ.
Anne Sumbul11 Bristol-Myers Squibb, Princeton, NJ.
Andrew Grigg12 Austin Hospital and Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.
Roche (Switzerland) · CHGilead Sciences (United States) · USTakeda (United States) · USJanssen (Belgium) · BEBristol-Myers Squibb (United States) · USEmory University · US

Funding

Targetable Immune Evasion Pathways in Hodgkin LymphomaR01CA161026 · NCI · DANA-FARBER CANCER INST · PI SHIPP, MARGARET A · 2011 to 2020
$4.0M
NCI NIH HHS R01 CA161026
6 · The paper itself

Abstract

purposeTreatment options are limited for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Tumor cells can exploit the programmed death-1 checkpoint pathway to evade immune surveillance. In the current study, we evaluated the efficacy and safety of programmed death-1 blockade by nivolumab in patients with relapsed/refractory DLBCL.

methodsIn this phase II, open-label study, patients with relapsed/refractory DLBCL who were ineligible for autologous hematopoietic cell transplantation (auto-HCT) or who had experienced failure with auto-HCT received nivolumab 3 mg/kg every 2 weeks. We assessed the efficacy and safety of nivolumab as well as genetic alterations of 9p24.1.

resultsAmong 121 treated patients, patients in the auto-HCT-failed cohort (n = 87) received a median of four nivolumab doses and a median of three doses were administered to those in the auto-HCT-ineligible cohort (n = 34). At a median follow-up of 9 months in the auto-HCT-failed cohort and 6 months in the auto-HCT-ineligible cohort, independently assessed objective response rates were 10% and 3%, and median durations of response were 11 and 8 months, respectively. Median progression-free survival and overall survival were 1.9 and 12.2 months in the auto-HCT-failed cohort and 1.4 and 5.8 months in the auto-HCT-ineligible cohort respectively. All three patients with complete remission-3% of the auto-HCT-failed cohort-had durable response (11 or more, 14 or more, and 17 months). Treatment-related grade 3 and 4 adverse events were reported in 24% of patients. The most common were neutropenia (4%), thrombocytopenia (3%), and increased lipase (3%). Of all evaluable samples for 9p24.1 analysis, 16% exhibited low-level copy gain and 3% had amplification.

conclusionNivolumab monotherapy is associated with a favorable safety profile but a low overall response rate among patients with DLBCL who are ineligible for auto-HCT or who experienced failure with auto-HCT. Genetic alterations of 9p24.1 are infrequent in DLBCL.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalChromosomes, Human, Pair 9Disease ProgressionFemaleHematopoietic Stem Cell TransplantationHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNivolumabProgrammed Cell Death 1 ReceptorProgression-Free SurvivalRemission InductionAntineoplastic Agents, ImmunologicalNivolumabPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID30620669
PMCPMC6528729
OpenAlexW2909334052

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.